Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

24.65USD
12:51pm EDT
Change (% chg)

$0.55 (+2.28%)
Prev Close
$24.10
Open
$24.20
Day's High
$24.70
Day's Low
$24.00
Volume
15,687
Avg. Vol
48,954
52-wk High
$28.25
52-wk Low
$12.35

Latest Key Developments (Source: Significant Developments)

Revance announces positive 24-week duration of effect in interim results from phase 2 cervical dystonia trial
Monday, 12 Dec 2016 04:05pm EST 

Revance Therapeutics Inc : Revance Therapeutics Inc - RT002 injectable appeared to be generally safe and well-tolerated . Revance Therapeutics Inc - RT002 injectable displayed clinically significant impact on cervical dystonia signs and symptoms . Revance Therapeutics Inc - these RT002 results are preliminary, with final results expected in first half of 2017 .Revance announces positive 24-week duration of effect in interim results from phase 2 cervical dystonia trial.  Full Article

Revance expects FY cash burn in range of $90 to $100 mln
Thursday, 4 Aug 2016 04:05pm EDT 

Revance Therapeutics Inc : Revance releases second quarter 2016 results . Expects its cash burn for 2016 to be in range of $90 to $100 million .Qtrly loss per share $0.88.  Full Article

Revance Therapeutics plans to initiate global phase 3 program in second half of 2016
Thursday, 14 Jul 2016 04:02pm EDT 

Revance Therapeutics Inc : Revance Announces Completion Of Pre-Phase 3 meeting with FDA for rt002 injectable to treat glabellar lines . Company plans to initiate global phase 3 program in second half of 2016 .Co's phase 3 program will include two placebo-controlled pivotal studies conducted at multiple sites in US and Canada.  Full Article

Revance reports results for RT001 topical Phase 3 trial for lateral canthal lines
Monday, 13 Jun 2016 04:01pm EDT 

Revance Therapeutics Inc : Revance reports results for RT001 topical Phase 3 trial for lateral canthal lines . RT001 topical generally appeared to be well-tolerated in study . In realise 1, daxibotulinumtoxina topical gel (RT001) did not achieve its co-primary and other endpoints . Do not plan to continue development of RT001 topical for crow's feet . Based on results, have decided not to pursue current clinical development plan for RT001 in axillary hyperhidrosis .Now expect its cash and investments to fund its operations into Q2 of 2018.  Full Article

Revance releases Q1 2016 results
Monday, 9 May 2016 04:05pm EDT 

Revance Therapeutics Inc : Reaffirms its 2016 full year guidance . Net loss for q1 ended march 31, 2016 was $19.9 million .Revance releases first quarter 2016 results.  Full Article

Revance Therapeutics, Inc reports positive 6-month duration in BELMONT Study
Thursday, 29 Oct 2015 07:00am EDT 

Revance Therapeutics, Inc:Says announced positive 24-week results today from its multi-center Belmont phase 2 active comparator study of injectable rt002.6-month duration of effect in Belmont study is statistically significant compared to botox cosmetic.Says all dose levels of rt002 achieved statistically significant, investigator-reported efficacy compared to placebo at week 4.Says all dose levels of rt002 appear to be safe and well tolerated.  Full Article

BRIEF-Revance Q2 ‍loss per share $0.90​

* Revance Therapeutics Inc - ‍reaffirmed its financial guidance provided in January 2017​